Brokerages Set Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) PT at $60.86

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has earned an average recommendation of “Buy” from the nine brokerages that are presently covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have covered the stock in the last year is $60.8571.

Several equities analysts have commented on KNSA shares. Jefferies Financial Group increased their target price on Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Citigroup increased their target price on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, June 17th. Finally, Wedbush raised their price objective on Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 29th.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, CEO Sanj K. Patel sold 483,654 shares of the firm’s stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $51.86, for a total transaction of $25,082,296.44. Following the completion of the transaction, the chief executive officer directly owned 431,904 shares in the company, valued at $22,398,541.44. This trade represents a 52.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 2,367 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $48.58, for a total value of $114,988.86. Following the transaction, the chief operating officer owned 12,029 shares of the company’s stock, valued at $584,368.82. This trade represents a 16.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 653,301 shares of company stock valued at $34,046,073 over the last ninety days. Insiders own 51.98% of the company’s stock.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds have recently made changes to their positions in KNSA. Qube Research & Technologies Ltd grew its stake in Kiniksa Pharmaceuticals International by 277.8% during the second quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after purchasing an additional 653,236 shares during the period. Rubric Capital Management LP grew its stake in Kiniksa Pharmaceuticals International by 15.6% during the second quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock worth $108,184,000 after purchasing an additional 526,567 shares during the period. Bank of America Corp DE grew its stake in Kiniksa Pharmaceuticals International by 220.9% during the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after purchasing an additional 506,576 shares during the period. Cubist Systematic Strategies LLC grew its stake in Kiniksa Pharmaceuticals International by 213.2% during the second quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after purchasing an additional 447,536 shares during the period. Finally, Spruce Street Capital LP acquired a new stake in Kiniksa Pharmaceuticals International during the fourth quarter worth approximately $17,943,000. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals International Stock Performance

Kiniksa Pharmaceuticals International stock opened at $55.11 on Wednesday. The company has a market capitalization of $4.24 billion, a PE ratio of 61.23 and a beta of 0.12. Kiniksa Pharmaceuticals International has a 12 month low of $26.27 and a 12 month high of $59.87. The stock has a 50-day moving average price of $51.02 and a two-hundred day moving average price of $46.37.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its earnings results on Tuesday, April 28th. The company reported $0.27 EPS for the quarter, beating the consensus estimate of $0.18 by $0.09. The firm had revenue of $214.27 million during the quarter, compared to the consensus estimate of $206.11 million. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business’s quarterly revenue was up 55.5% on a year-over-year basis. During the same period last year, the company earned $0.11 earnings per share. As a group, analysts predict that Kiniksa Pharmaceuticals International will post 1.24 earnings per share for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.